AzTrials
AzTrials

Peripheral Artery Disease (PAD)NCT07226193

Detecting Peripheral Artery Disease With the Pulse

A study testing Segmental pulse arrival time assessment in people with Peripheral Artery Disease (PAD), run by University of Nebraska at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

1) The purpose of this study is to assess segmental pulse arrival time (PAT) as an alternative biomarker to detect lower-extremity peripheral artery disease (PAD), and to investigate the impacts of local skin heating and foot elevation. The secondary purpose will be to investigate the impacts of age on segmental PAT. Read more about this study

Who is it for?
Ages 19 years and olderHealthy volunteers can take part
Conditions the study is for
Peripheral Artery Disease (PAD)
What is being tested?
Segmental pulse arrival time assessment
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteUnited States
Study dates
5 Feb 2026to 1 Jan 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • be able to provide written informed consent
  • be 19 years of age or older
  • having or not having a diagnosis of peripheral artery disease

Who cannot join

  • having a current or pervious aortic aneurysm with or without previous intervention
  • having previous revascularization surgeries (open or endovascular) of the legs or aorta
  • having walking impairments independent of lower-limb ischemia (e.g., musculoskeletal injury)
  • having gangrene or ulcers of the toes/feet
  • being currently pregnant or breastfeeding

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Cody P Anderson, PhD contact

402-554-2876

codypanderson@unomaha.edu

United States1 site, 1 recruiting
  • University of Nebraska at Omaha Health Science Collaborative

    Omaha, Nebraska, 68182

    Cody P Anderson, PhD, 402-237-6539, codypanderson@unomaha.edu

    Recruiting

Other trials in United States

About this study

Official title: Pulse Arrival Time as an Alternative Biomarker to Detect Lower-Extremity Peripheral Artery Disease

  1. The purpose of this study is to assess segmental pulse arrival time (PAT) as an alternative biomarker to detect lower-extremity peripheral artery disease (PAD), and to investigate the impacts of local skin heating and foot elevation. The secondary purpose will be to investigate the impacts of age on segmental PAT. The subject population will include any adults 19 years of age or older with or without PAD. Exclusion criteria include having an aortic aneurysm with or without previous intervention, previous revascularization surgeries of the arteries in the legs/aorta, walking impairments independent of PAD, gangrene or ulcers of the toes/feet, and currently pregnant or breastfeeding. 3) All aims of the present study will be completed with a single laboratory visit. Descriptive measurements will include height, weight, age, sex, body fat percentage, and self-reported medication and health history. Subjects will lie in the supine position for 20-min. After rest, either the ankle-brachial index (ABI) or PAT will be assessed. After 10-min of further rest, the other measurement will be performed. ABIs will be assessed according to current guidelines: blood pressures will be assessed in the dorsal pedis and tibialis posterior arteries of both legs and the brachial arteries of both arms using a blood pressure cuff and Doppler ultrasound. PAT will be simultaneously assessed in both arms and legs using an investigational device with a 3-lead electrocardiogram sensor and four photoplethysmography (PPG) sensors. A PPG sensor will be applied to a finger on each hand and both big toes. Signals will be collected for 15-min with finger and toe sensor temperatures at 30 C. Toe sensor temperature will then be elevated to 45 C for 15-min. Finally, toe sensor temperature will remain at 45 C, and the feet will be elevated 8-in with a soft cushion for 15-min. Blood pressure in the arm and legs will be assessed at the end of each stage. Thermal images of the fingers and toes will be assessed before using the investigational device and after each stage. Subjects will then participate in a 6-min walking test (6MWT) to objectively establish walking capacity. The 6MWT will be performed in accordance with current guidelines. Segmental PATs will be compared with ABI and 6-min walking time to determine if segmental PATs can predict lower-extremity PAD (ABI) and the associated walking impairment (6MWT). This study is expected to last ~2.5hrs. 4) There will be no follow-up.
Read the detailed description

Specific Aim 1: Determine if segmental pulse arrival times can predict lower-extremity peripheral artery disease assessed with ankle-brachial index and the 6-min walking test.

Specific Aim 2: Determine if local skin heating of the toes and foot elevation improves the prediction of peripheral artery disease using segmental pulse arrival times.

Specific Aim 3: Determine the effects of age on segmental pulse arrival times.

After the process of informed consent, descriptive measurements will be assessed. Descriptive measures include height, weight, body composition, age, and sex. Height and weight will be assessed with a standard stadiometer and scale, respectively. Body composition will be assessed non-invasively with bio-electric impedance analysis (Omron HBF-306C Handheld Scanner, OMRON Healthcare, Kyoto, Japan). Bioelectric impedance devices send a small electric current through the body and estimates body fat percentage based on the impedance to electrical flow through the body segments. Our bio-electric impedance device creates a circuit between the hands and feet of the subject to estimate body fat percentage. The electric current used in bioelectric impedance devices is very small and cannot be felt by the participant. Subjects will also self-report their medication and health history.

After the assessment of descriptive measurements, subjects will rest in the supine position for 20-min. After 20-min of rest, the subjects will have either ankle-brachial index (ABI) or segmental pulse arrival times (PATs) assessed. After a 10-min period of rest, the other measurement will be assessed (either ABI or PAT). The order of ABI and PAT will be randomized, and all subjects will have ABI and PAT assessed.

1a) Assessment of PAT with the Investigational Device: The subjects will be instrumented with an investigational device comprised of an array of four photoplethysmography (PPG) sensors and one 3-lead electrocardiogram (ECG) sensor. Electrocardiogram is a non-invasive technique that is used to monitor the electrical dipoles generated by membrane potentials within the myocardium and electrical conduction systems of the heart. PPG is a non-invasive technique to assess hemoglobin content within the microcirculation of the skin. Our PPG sensors are applied superficially on the skin and shines continuous-intensity green light into the skin (580 nm). The green light is absorbed by hemoglobin. Therefore, by the modified Beer-Lambert principle, the amount of light reflected back to the PPG unit gives an index of hemoglobin content within the microvasculature. The PPG and ECG sensors are integrated into a microcontroller (small computer), which reads the voltages of the sensors and displays the data in real time in a custom computer software. Each PPG sensor will have a skin-safe double-sided adhesive attached to the sensor housing. A PPG sensor will be adhered to a finger on the palmar side of both hands. A PPG sensor will be adhered to the plantar aspect of both big toes. Altogether, there will be one PPG sensor per hand and one PPG sensor per foot. The ECG sensor will be applied to form limb leads: one electrode per wrist on the ventral aspect of the forearm and one electrode on a hair-free portion of the left leg. If an adequate ECG signal is not obtained using limb leads, then chest leads will be utilized. In this configuration, electrodes will be placed inferior to the left and right clavicle, and medial to the shoulders, and one electrode will be placed on the left lateral aspect of the ribcage near the apex of the heart. Once all sensors have been placed, the subject will rest in the supine position. Next, the temperature of the sensor housings attached to the fingers and toes will be warmed to 30 C, which is thermoneutral with skin temperature, and subjects will rest for 15-min. Blood pressure will then be assessed in the arm and legs with a standard automatic blood pressure device. After 15-min of signal collection, the toe sensor housings will be heated to 45 C to warm up the skin of the toes, and the finger sensor housings will remain warmed at 30 C for an additional 15-min. Blood pressure will then be assessed in the arm and legs with a standard automatic blood pressure device. Next, the lower legs will be elevated 8-in with a soft cushion. The toe sensors will remain heated at 45 C, and the finger sensors will remain at 30 C. Signals will be collected continuously for an additional 15-min. Finally, blood pressure will then be assessed in the arm and legs with a standard automatic blood pressure device. For all conditions, PAT will be calculated for each arm and each leg as the difference in time between the R-wave appearing in the ECG signal and the pulse wave appearing in the distal PPG signals. All four PAT values will be used to develop a composite score to estimate the presence of lower-extremity PAD. Leg asymmetry will be assessed with the ratio of PATs from left and right legs. Atherosclerotic plaque-mediated pulse wave slowing will be assessed as the ratio of PATs in the arms compared to the legs. The product of these ratios forms the composite score to detect lower-extremity PAD, which is sensitive to both 1) asymmetry in PATs in the legs (may indicate unilateral lower-extremity PAD) and 2) longer PATs in the legs compared to the arms (may indicate the presence of lower-extremity PAD).

1b) Thermal Imaging:A thermal imaging camera (FLIR T540) will be used to take thermal images of the skin where the PPG sensors will be/were applied. Thermal images will be taken 1) prior to all sensors being applied, 2) after warming the finger and toe sensors to 30 C, 3) after warming the finger sensors to 30 C and the toe sensors to 45 C without leg elevation, and 4) after warming the finger sensors to 30 C and the toe sensors to 45 C with leg elevation. The purpose of using the thermal camera is to document the local skin temperature before and after using the investigational device at each setting. The thermal camera will automatically select the warmest region of the image and document the temperature. Of note, the thermal imaging camera will be zoomed in on the fingers and toes where the PPG sensors were located, and no identifiable body parts (e.g., face) or clusters of body parts (e.g., zoomed out images) will be included in the thermal images. Therefore, the risk of identifying subjects with the thermal images will be minimized.

  1. Assessment of ABI: ABI will be assessed according to current guidelines established by the American Heart Association and the American College of Cardiology. Blood pressures will be assessed in both legs and in both arms. For all blood pressure assessments, the blood pressure cuff will be manually inflated to a supra-systolic pressure. During slow manual cuff deflation, a Doppler ultrasound (non-invasive) will be used to listen for the first Korotkoff sound, which is the systolic blood pressure. Using this procedure, the systolic blood pressure will be quantified for both the ipsilateral dorsalis pedis and posterior tibial arteries for both legs. Furthermore, systolic blood pressure will be assessed in the brachial arteries of both arms. ABI will be quantified as the ratio of the higher systolic blood pressure in the legs divided by the higher systolic blood pressure in the arms.
  2. 6-minute walking test: After the assessments of ABI and PAT, subjects will participate in a 6-min walking test to objectively quantify exercise capacity. Two cones will be separated by 30 m on a straight and flat walkway. Subjects will be instructed to walk back and forth between the cones as fast as they can for 6-min to achieve the farthest distance that they can. Subjects will be allowed to rest during the test, but the stopwatch time will not be stopped. All components of the test will be explained clearly prior to performing the test. Comprehension of the objectives of the test will be confirmed prior to initiating the test. Prior to performing the 6-min walking test, blood pressure, heart rate, and the rating of perceived exertion (RPE) will be recorded in the seated position. Furthermore, blood pressure, heart rate, and RPE will be recorded with the subject in the seated position immediately after exercise and every 5-min thereafter until the pre-exercise heart rate and blood pressure are re-established (w/in +/-5 beats and +/-5 mmHg) in alignment with American College of Sports Medicine guidelines.

The study duration is expected to be ~2.5 hrs, and there will be no follow-up.

Being tested
Segmental pulse arrival time assessment
Keywords
pulse arrival time, atherosclerosis, peripheral artery disease, portable peripheral artery disease detection
Medical subject headings
Peripheral Arterial Disease, Atherosclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Segmental pulse arrival time assessmentDevice

    A proprietary device has been developed to obtain segmental pulse arrival times in the arms and legs. Using this information, the propagation time of the pulse is being investigated as a biomarker to detect the presence of lower-extremity atherosclerosis. Furthermore, the impacts of aging on the biomarker will be assessed.

Study groups in NCT07226193
Study groupRoleWhat they receive
Laboratory Visit #1ExperimentalDuring the first and only laboratory visit, subjects will be tested 1) with the experimental device, 2) an ankle-brachial index will be performed, and 3) a 6-min walking test will be performed.
Receives: Device: Segmental pulse arrival time assessment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Segmental pulse arrival times

    Pulse arrival time will be assessed in both arms and legs with the investigational device

    Measured: Day 1

  2. Ankle-brachial index

    Segmental blood pressures in the arms and ankles will be assessed as an index of the presence and/or severity of lower-extremity atherosclerosis. The ankle-brachial index is the standard screening assessment for peripheral artery disease in the lower-extremities.

    Measured: Day 1

  3. 6-min walking distance

    The 6-min walking test is a standard assessment of mobility in older adults and in patients with peripheral artery disease. The 6-min walking test will be performed to quantify the level of walking impairment in patients with peripheral artery disease.

    Measured: Day 1

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Nov 2025
  2. Study start5 Feb 2026
  3. Primary completion1 Jan 2028 (estimated)
  4. Study completion1 Jan 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Model description
To address the objective of Specific Aim #1 \& #2, two groups of participants are defined as needing to complete the study: 1) patients with peripheral artery disease and 2) age-matched controls. All participants will participate in a single laboratory visit where 1) the experimental device will be tested, 2) an ankle-brachial index will be performed, and 3) a 6-min walking test will be performed. To address the objectives of Specific Aim #3, two groups of participants are defined as needing to complete the study: 1) younger adults (19-54 yrs) and 2) older adults (+55 yrs). All participants will participate in a single laboratory visit where 1) the experimental device will be tested, 2) an ankle-brachial index will be performed, and 3) a 6-min walking test will be performed.
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07226193
Sponsor's protocol ID
0685-25-EP
Status last verified
Feb 2026
First submitted
30 Oct 2025
Last updated
17 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: Deidentified IPD will be shared upon request to journals for the purpose of publication. Specific IPD will include the primary outcome measures of this study.

Questions about this trial

What is this clinical trial studying?

A study testing Segmental pulse arrival time assessment in people with Peripheral Artery Disease (PAD), run by University of Nebraska at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Cody P Anderson, PhD (402-554-2876, codypanderson@unomaha.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Segmental pulse arrival times (time frame: Day 1). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in